Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1139/y69-073 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Best evidence summary for the management of exercise in patients with central venous access devices.
J Vasc Access
January 2025
Department of Nasopharyngeal Carcinoma, Sun Yat-sen University Cancer Center, Guangzhou, P.R. China.
Background: Central venous access devices (CVAD) are widely used in patient care, providing an essential, reliable pathway for patients to receive chemotherapy, long-term infusions, and nutritional support. However, a system of exercise management has not been developed in patients with CVAD.
Purpose: To evaluate and summarize the evidence for management exercise in patients with CVAD and provide guidance for clinical practice.
Success Rate of Endoscopic Third Ventriculostomy in Children Younger Than 1 Year With Idiopathic Congenital Aqueductal Stenosis and Long-term Follow-up.
J Child Neurol
January 2025
Department of Neurosurgery, University Hospital Ostrava, Ostrava, Czech Republic.
Introduction: The indication for endoscopic third ventriculostomy is often contested in children younger than 1 year. This study aims to establish the benefits of this modality in children with idiopathic congenital aqueductal stenosis.
Methods: Retrospective analysis was performed on patients <1 year old with idiopathic congenital aqueductal stenosis undergoing endoscopic third ventriculostomy between 2004 and 2020.
Optimizing the life of vascular access during follow-up.
J Cardiovasc Surg (Torino)
February 2025
Department of Vascular Surgery, ASST Settelaghi Universitary Teaching Hospital, University of Insubria, Varese, Italy.
Optimizing the longevity of vascular access in hemodialysis patients remains a critical aspect of patient care, given the significant role of arteriovenous fistulas (AVFs) and arteriovenous grafts (AVGs) in enabling effective dialysis. Vascular access complications, such as stenosis, thrombosis, and cannulation-related damage, continue to challenge both the functionality and the sustainability of these access points. Recent advancements underscore the importance of a robust follow-up strategy, integrating clinical evaluations with diagnostic tools like color Doppler ultrasound (CDU) and emerging interventional approaches such as drug-coated balloon (DCB) angioplasty.
View Article and Find Full Text PDFAdvancements in vascular access for hemodialysis: personalization, innovation, and long-term care.
J Cardiovasc Surg (Torino)
February 2025
Department of Surgery, Centre Hospitalier de Luxembourg, Luxembourg, Luxembourg -
Thigh Injections of Cabotegravir + Rilpivirine in Virally Suppressed Adults With Human Immunodeficiency Virus Type 1: A Substudy of the Phase 3b ATLAS-2M Study.
Clin Infect Dis
January 2025
ViiV Healthcare, Durham, North Carolina, USA.
Background: Cabotegravir + rilpivirine (CAB + RPV) administered via intramuscular gluteal injections is the first complete long-acting regimen for maintaining human immunodeficiency virus type 1 (HIV-1) virologic suppression. We present substudy results on short-term repeat intramuscular CAB + RPV long-acting thigh injections in participants with ≥3 years of experience with gluteal administration during the ATLAS-2M study.
Methods: Substudy phases included screening, thigh injection (day 1-week 16), and return to gluteal injection (week 16-week 24).
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!